Cizumab 400 mg contains Bevacizumab, a recombinant humanized monoclonal antibody that targets a key protein involved in tumour blood supply.
It is given as an intravenous infusion, often alongside chemotherapy or other cancer drugs, and has become an important treatment option for several advanced solid tumours.
By targeting the way tumours build new blood vessels, Cizumab can help shrink or stabilise cancers, improving survival and quality of life.

Mechanism of Action

Bevacizumab works by binding to vascular endothelial growth factor (VEGF), a protein that stimulates the growth of new blood vessels (a process called angiogenesis).

• Many tumours overproduce VEGF to grow their own blood supply, allowing them to get more oxygen and nutrients.

• By blocking VEGF, bevacizumab starves tumours of the blood supply they need to grow and spread.

  Uses / Indications

  Cizumab is used in combination with chemotherapy for several advanced cancers, including:

  • Metastatic colorectal cancer, usually with fluoropyrimidine-based regimens (like FOLFOX or FOLFIRI).

  • Advanced non-squamous non-small cell lung cancer (NSCLC).

  • Metastatic cervical cancer.

  • Recurrent glioblastoma (a type of brain tumour).

  • Metastatic renal cell carcinoma, often combined with interferon.

  • Also used in ovarian and fallopian tube cancers in certain protocols.

    Adverse Effects

    Because bevacizumab affects blood vessel formation throughout the body, some side effects relate to its impact on normal vessel maintenance and healing.

    Common side effects include:

    • High blood pressure (hypertension) – often requiring medication.

    • Fatigue, mild headache.

    • Delayed wound healing or minor bleeding (like nosebleeds).